Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (5695)	11/20/1998 7:48:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 6136

The current interest in immune therapy is really giving AGPH a kick. An editorial in tomorrow's Lancet, including........ "Frances Gotch (Chelsea and Westminster Hospital, London, UK) believes that Remune (Immune Response Corp, Carlsbad, CA, USA)--killed, gp120-depleted HIV-1 mixed with incomplete Freund's adjuvant--is the "best candidate vaccine" for further study. Data presented in Glasgow suggest that Remune can induce HIV-1-specific immune responses that are of the same magnitude as those seen in HIV-1-positive people with non-progressive disease. An ongoing phase III study--the first to test an immune strategy--will show whether these responses translate into clinical benefit. Another approach currently being tested by Gotch in the Chelsea Immunotherapy Study involves the addition of IL-2 to Remune to enhance HIV-1-specific responses."